ArticleClinical drug investigation2022

Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis.

Young Eun Shin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.